Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cequa vs Xiidra for Central Corneal Staining
NCT04172961Phase 4Unknown
- Sponsor
- Toyos Clinic
- Start
- Feb 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cyclosporine 2% ophthalmic solution in dry eye syndrome (DED) (2 arms), sponsored by Toyos Clinic. Primary endpoint: Change in central corneal staining at 90 days. Status: unknown.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04172961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172961.